Atrial peptide derivatives
CA 2033198 A1 · Owner: Lucas, Scott D. · Inventors: Lucas, Scott D.; Davidsen, Steven K.; Rockway, Todd W.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Novel atrial peptides of the formula are disclosed which have useful hypotensive natriuretic and, diuretic activity and in which R1 is selected from hydrogen AcetylArg, Aha, Arg, Cit, His, Lys, Orn and Ser-Ser; R2 is a sulfur-containing group; R3 is a hydrophobic amino acid or dipeptide; R4 is a dipeptide spacer, or a tripeptide containing a dipeptide spacer plus a basic amino acid residue; R5 is a hydrophobic amino acid; R6 is a peptide of up to three amino acids; R7 is selected from Cha, Phe Cha-Arg, Phe-Arg, (D)Phe-Arg, Phe-(D)Arg Phe?Arg, Leu-Arg, Ala-Arg, Arg and, Gly-Ala; and R8 is a sulfur-containing group as well as, pharmaceutically acceptable salts esters and amides thereof.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed May 23, 1990. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended May 23, 2010.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by May 23, 2012.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.